MedTrace Logo

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

NCT02172573 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2014-06-24

No results posted yet for this study

Summary

The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).

Conditions

  • Parkinson Disease

Interventions

DRUG

Pramipexole

DRUG

Bromocriptine

DRUG

Placebo pramipexole

DRUG

Placebo bromocriptine

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Primary Completion
2000-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172573 on ClinicalTrials.gov